SOURCE: Implant Sciences Corporation
WILMINGTON, MA--(Marketwire - Sep 19, 2012) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has appointed Mr. Jimmy Mo as its Southeast Asia Sales Manager.
Mr. Mo has more than 20 years of experience in the security industry. His background includes sales and marketing roles for x-ray baggage inspection systems, metal detection systems, and explosives trace detection systems, as well as first-hand experience installing and maintaining the security equipment at the former Hong Kong International Airport.
Mr. Mo was Director, Asia Pacific Sales and Marketing for GE Ion Track following GE Security's acquisition of Ion Track Instruments. While at Ion Track Instruments, Mr. Mo succeeded in opening new markets and delivered significant contracts valued in the millions of dollars. He also served as Director, Asia Pacific Sales and Marketing, for American Science and Engineering, a leading provider of x-ray systems, advanced cargo, parcel, and personnel inspection systems, where he established key relationships with governments throughout the region.
Dr. Bill McGann, Chief Operating Officer of Implant Sciences and co-founder of Ion Track Instruments, commented, "I had the pleasure of working with Jimmy at Ion Track where he was instrumental in opening and creating demand for products in Asia and Southeast Asia. He's an expert in security technologies and has key relationships in that region. We welcome him to our growing Implant Sciences team as we look to further penetrate the Southeast Asia market."
"Having yet another accomplished industry veteran join our team at Implant Sciences is a testament to the next generation technology and potential of our Company," stated Dr. Darryl Jones, Implant Sciences' Vice President of Sales and Marketing. "With Jimmy joining us, we have once again enhanced our management team, which is particularly important as we ready our products and distribution partners for takeoff."
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.